ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
COVID vaccines

US startup to test small-dose COVID vaccine in Japan this summer

VLP Therapeutics jab requires less than one-tenth amount of other mRNA shots

A mock vaccine exercise in Japan: VLP Therapeutics estimates the dosage required per person for its vaccine would be 1 to 10 micrograms, which is 1% to 10% the amount required for other RNA-based vaccines.   © Reuters

TOKYO -- A new type of coronavirus vaccine that requires less than one-tenth the dosage of existing shots made by Pfizer and others is nearing clinical trials in Japan, with the developer hoping to counter new variants of the virus.

U.S.-based VLP Therapeutics will apply for Japanese approval by June, and aims to start clinical trials by the summer. The first phase would involve dozens of participants at Oita University Hospital.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more